Related Experiment Videos

Targeting new cellular disease pathways in autosomal dominant polycystic kidney disease

Ming-Yang Chang1, Albert C M Ong2,3

  • 1Kidney Research Center, Department of Nephrology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

Insights

Autosomal dominant polycystic kidney disease (ADPKD) is a common inherited kidney disease. Newer research reveals broader cellular changes beyond the classic phenotype, offering new therapeutic targets for ADPKD.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Genetics

Background:

  • Autosomal dominant polycystic kidney disease (ADPKD) is the leading inherited cause of end-stage renal failure.
  • The classic cellular cystic phenotype involves altered proliferation, apoptosis, fluid secretion, extracellular matrix, and cilia function.
  • Emerging evidence suggests a broader cellular cystic phenotype in ADPKD.

Purpose of the Study:

  • To review newer cellular pathways implicated in ADPKD pathogenesis.
  • To explore the roles of altered metabolism, autophagy, inflammation, oxidative stress, and epigenetic modifications in ADPKD.
  • To discuss potential novel therapeutic targets based on these pathways.

Main Methods:

  • Literature review of recent research on ADPKD cellular pathogenesis.
  • Analysis of evidence linking novel cellular pathways to cyst initiation, growth, and progression.
  • Synthesis of information to identify potential therapeutic strategies.

Main Results:

  • The cellular cystic phenotype in ADPKD extends beyond classic features.
  • Altered metabolism, autophagy, inflammation, oxidative stress, and epigenetic modifications are increasingly recognized as critical factors.
  • These pathways are implicated in various stages of ADPKD, from initiation to progression.

Conclusions:

  • Understanding these expanded cellular pathways is crucial for a comprehensive view of ADPKD.
  • Novel therapeutic strategies targeting metabolism, autophagy, inflammation, oxidative stress, and epigenetics hold promise for ADPKD treatment.
  • Further research into these newer pathways could lead to more effective interventions for patients with ADPKD.

Related Concept Videos